Product Overview
This precise 1:1 co-lyophilized blend combines a synthetic gastric-derived pentadecapeptide (BPC-157) with an actin-sequestering protein derivative (TB-500 / Thymosin $\beta$4). In laboratory environments, this dual-peptide complex operates synergistically on the angiogenic and cytoskeletal dynamics axes. It provides advanced researchers with a comprehensive tool for observing concurrent pathways involving extracellular matrix (ECM) remodeling, cellular migration, and localized cytoprotection.
Designed strictly for in vitro tissue modeling and animal studies, this blend allows for the simultaneous modulation of nitric oxide (NO) pathways and actin polymerization cascades. The compounds are synthesized and co-lyophilized under stringent analytical grade standards to ensure absolute sequence integrity and an ultra-high purity profile, preventing immunogenic cross-contamination during complex research protocols.
Technical Specifications
- Sequence (BPC-157): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Sequence (TB-500): Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
- Molecular Formula: C62H98N16O22 (BPC-157) | C212H350N56O78S (TB-500)
- Molecular Weight: 1419.5 g/mol (BPC-157) | 4963.5 g/mol (TB-500)
- Purity: >99% (HPLC Verified for both compounds)
- Endotoxin: <0.5 EU/mg (Suitable for sensitive in vitro assays)
- Solvent: Solvent not included (Sold Separately)
- Format: Co-lyophilized Solid (Sealed Vial)
- Appearance: White crystalline powder
- Grade: Laboratory / Analytical Grade
Variant Breakdown
- 10mg Vial: Co-lyophilized laboratory reagent containing 5mg BPC-157 and 5mg TB-500.
- 20mg Vial: Co-lyophilized laboratory reagent containing 10mg BPC-157 and 10mg TB-500.
- 30mg Vial: Co-lyophilized laboratory reagent containing 15mg BPC-157 and 15mg TB-500.
- Closure: Rubber stopper with flip-off aluminium seal.
Research Mechanism (Mechanism of Action)
Current scientific models indicate that the concurrent administration of BPC-157 and TB-500 triggers complementary, cascading cellular responses via distinct but parallel receptor pathways. The synergistic mechanism can be broken down by its constituent elements:
- VEGFR2 Upregulation & FAK-Paxillin Activation (BPC-157): BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and modulates endothelial nitric oxide synthase (eNOS) pathways. This promotes rapid angiogenesis and cellular survival under hypoxic conditions. Concurrently, it activates the focal adhesion kinase (FAK) and paxillin pathways, establishing the scaffolding necessary for accelerated fibroblast migration and deep-tissue ECM remodeling.
- Actin Sequestration & MMP Upregulation (TB-500): TB-500 functions as a primary actin-sequestering molecule. By selectively binding to G-actin monomers, it prevents their unregulated polymerization into F-actin. This steric hindrance fluidizes the cytoskeleton, dramatically enhancing cellular motility and chemotaxis. Furthermore, TB-500 upregulates matrix metalloproteinases (MMPs), enzymes essential for breaking down biological barriers to facilitate the migration of endothelial cells during network formation.
- Synergistic MOA: When introduced to isolated tissue cultures concurrently, BPC-157 drives the structural formation of new vascular networks, while TB-500 provides the necessary cytoskeletal fluidity and cellular precursors to populate those newly formed micro-vessels.
Quality Assurance
In regenerative and cellular motility research, the purity of a multi-peptide blend is critical. Substandard formulations or structural degradation can lead to unpredictable binding affinities and obscured study results. Our reagents are:
- HPLC Verified: >99% Purity for both active sequences within the co-lyophilized cake.
- Mass Spec Analyzed: To confirm the precise molecular weight and structural integrity of both BPC-157 and TB-500 post-lyophilization.
- TFA Removed: Minimized trifluoroacetic acid content to prevent cytotoxicity in sensitive primary cell lines.
Safety and Handling
WARNING: This product is intended for Laboratory Research Purposes and in vitro use Only.
- Research Only: Not intended for human consumption, diagnostic, or therapeutic use.
- Storage (Lyophilized): Store at -20°C for long-term preservation. Keep away from direct light.
- Storage (Reconstituted): Once reconstituted with an appropriate solvent, store at 2°C to 8°C and use within 14 to 28 days.
Standard Laboratory Reconstitution Protocol
This formulation features a co-lyophilized cake containing both a highly stable pentadecapeptide (BPC-157) and a larger, more structurally sensitive 43-amino acid peptide (TB-500). Because both molecules are hydrophilic, they are readily soluble in standard aqueous solvents.
For optimal preservation of the longer TB-500 peptide bonds during reconstitution, Sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) is the recommended laboratory solvent.
- Allow the lyophilized vial to equilibrate to ambient room temperature before removing the seal to prevent condensation within the vial.
- Introduce the solvent via the "drop-wise" method—directing the flow against the inner glass wall of the vial rather than directly onto the lyophilized cake. This prevents mechanical shearing of the delicate TB-500 sequence.
- Swirl the vial gently until the solution is completely clear and the dual-peptide matrix is fully dissolved. Do not shake vigorously, as agitation can denature the longer protein chains.
Scientific References
Regeneration or Risk? (2025) - A Narrative Review of BPC-157 for Musculoskeletal Healing. View Article
Thymosin beta-4 (2022) - improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells”View Article
Journal of Cell Science (2014) – Research detailing the mechanism of actin sequestration by Thymosin Beta-4 (TB-500). View Article
